Nonclinical assessment of abuse potential for new pharmaceuticals /

Mostrar otras versiones (1)

Nonclinical Assessment of Abuse Potential for New Pharmaceuticals offers a complete reference on the current international regulatory guidelines and details best practice methodology for the three standard animal models used to evaluate abuse potential: physical dependence, self-administration and d...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Markgraf, Carrie G. (Editor ), Hudzik, Thomas J. (Editor ), Compton, David R. (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam : Academic Press, 2015.
Temas:
Drugs > Overdose.
Opioids > Overdose.
Drug abuse.
Drug addiction.
Prescription Drug Misuse > prevention & control
Substance-Related Disorders > prevention & control
Drug Overdose
Substance-Related Disorders
Drug Evaluation, Preclinical
Models, Animal
M�edicaments > Surdosage.
Opio�ides > Surdosage.
Toxicomanie.
drug addiction.
drug abuse.
POLITICAL SCIENCE > Public Policy > Social Security.
POLITICAL SCIENCE > Public Policy > Social Services & Welfare.
Drug addiction
Drug abuse
Drugs > Overdose
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Front Cover; Nonclinical Assessment of Abuse Potential for New Pharmaceuticals; Copyright; CONTENTS; CONTRIBUTORS; FOREWORD; PREFACE; ACKNOWLEDGMENTS; Chapter 1
  • Nonclinical Assessment of Abuse Potential for New Pharmaceuticals in a Regulatory Space; 1. TERMINOLOGY; 2. ANIMAL MODELS OF ABUSE POTENTIAL; 3. REGULATION OF DRUGS OF ABUSE; 4. SCHEDULING; 5. SUMMARY; REFERENCES; Chapter 2
  • Neurochemistry of Abuse Liability Assessment and Primary Behavioral Correlates; 1. INTRODUCTION; 2. REWARD SYSTEM; REFERENCES; Chapter 3
  • Rat Self-Administration; 1. INTRODUCTION; 2. REGULATORY ISSUES.
  • 3. THE OPERANT CHAMBER SET UP4. THE TRAINING; 5. THE DRUG CONTINGENCIES; 6. THE TESTING; 7. DOSE-RESPONSE RELATIONSHIPS; 8. MAINTENANCE DRUG; 9. GENDER; 10. LIMITED VERSUS UNLIMITED ACCESS TO DRUG DURING TRAINING; 11. RESPONSE TOPOGRAPHY; 12. REINFORCING EFFICACY; 13. CONCLUSION; REFERENCES; Chapter 4
  • Nonhuman Primate Self-Administration in Assessments of Abuse Potential; 1. ASSESSMENT OF ABUSE POTENTIAL IN LABORATORY ANIMALS; 2. RATIONALE FOR USING NONHUMAN PRIMATES IN ASSESSMENTS OF ABUSE POTENTIAL; 3. STUDYING DRUG SELF-ADMINISTRATION IN NONHUMAN PRIMATES.
  • 4. STUDYING DRUG DEPENDENCE IN NONHUMAN PRIMATES5. CONCLUSIONS AND RECOMMENDATIONS; ACKNOWLEDGMENTS; REFERENCES; Chapter 5
  • Assessing Physical Dependence; 1. INTRODUCTION; 2. DEFINITIONS; 3. NEUROBIOLOGY OF WITHDRAWAL; 4. WITHDRAWAL: PRECIPITATED AND NONPRECIPITATED; 5. USE OF POSITIVE AND NEGATIVE CONTROLS IN THE WITHDRAWAL TEST; 6. ANIMAL MODEL OF NONPRECIPITATED WITHDRAWAL; 7. GENERAL CONSIDERATIONS; 8. GOOD LABORATORY PRACTICES; 9. REGULATORY GUIDANCE AND GLOBAL REGULATORY FRAMEWORK; 10. TIMELINES; 11. PHYSICAL DEPENDENCE TESTING OF LARGE MOLECULES.
  • 12. PHYSICAL DEPENDENCE TESTING IN HUMANS13. CONCLUSIONS; LIST OF ABBREVIATIONS; REFERENCES; Chapter 6
  • Drug Discrimination: Use in Preclinical Assessment of Abuse Liability; 1. FROM STATE DEPENDENCY TO DRUG DISCRIMINATION: A BRIEF HISTORY; 2. METHODOLOGY; 3. SOFTWARE; 4. TRAINING DRUGS; 5. DRUG DISCRIMINATION: TRAINING AND TESTING; 6. DATA INTERPRETATION: LEVELS OF GENERALIZATION; 7. THE DISCRIMINATIVE EFFECT; 8. TIME COURSE DETERMINATION; 9. PHARMACOKINETICS; 10. STRATEGIC PLACEMENT OF DRUG DISCRIMINATION IN THE ABUSE LIABILITY ASSESSMENT TOOLBOX.
  • 11. DRUG DISCOVERY AND DEVELOPMENT STRATEGIC USE OF DRUG DISCRIMINATIONREFERENCES; Chapter 7
  • Conditioned Place Preference as a Preclinical Model for Screening Pharmacotherapies for Drug Abuse; 1. INTRODUCTION; 2. BASIC PRINCIPLES OF CONDITIONED PLACE PREFERENCE; 3. APPLICATION OF CONDITIONED PLACE PREFERENCE TO MEDICATION DEVELOPMENT; 4. RECENT FINDINGS; 5. CONCLUSION; REFERENCES; Chapter 8
  • Utility of Intracranial Self-Stimulation in the Assessment of the Abuse Liability of New Pharmaceuticals; 1. INTRODUCTION.

Ejemplares similares